SAB Biotherapeutics (SABS) Debt Ratio (2020 - 2025)

SAB Biotherapeutics' (SABS) quarterly Debt Ratio came in at 0.01 in Q4 2022, up 249.68% on a QoQ basis from 0.0 in Q4 2020.

Analysis

SAB Biotherapeutics (SABS) Debt Ratio (2020 - 2025) Analysis & Trends

SAB Biotherapeutics (SABS) has 2 years of Debt Ratio data on file, last reported at 0.01 in Q4 2022.

Quarterly Debt Ratio changed N/A year-over-year to 0.01 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 0.01 (changed N/A YoY) and the FY2022 annual result came in at 0.01, changed N/A from the prior year.
Debt Ratio climbed to 0.01 in Q4 2022, from 0.0 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.01 in Q4 2022 to a low of 0.0 in Q4 2020.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	0.05
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	0.05
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	0.12
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	0.47
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	0.26
10	SAB Biotherapeutics	296.68 Mn	296.68 Mn	-	-

Historic Data

Download Data